Gender-related outcomes in robot-assisted radical cystectomy: A multi-institutional study

Hyun Jung Jin¹, Ji Sung Shim¹, Tae Gyun Kwon², Tae-Hwan Kim², Seung Hyun Jeon¹, Sang Hyub Lee³, Sung Gu Kang³, Jong Kil Nam⁴, Wan Suk Kim⁵, Byung Chang Jeong⁵, Jong Jin Oh⁶, Sang Chul Lee⁷, Ji Youl Lee⁸, Sung-Hoo Hong⁸, Koon Ho Rha⁸, Woong Kyu Han⁹, Won Sik Ham⁹, Young Goo Lee¹⁰, Yong Seong Lee¹⁰, Sung Yul Park¹¹, Young Eun Yoon¹¹, Ja Hyeon Ku¹, Seok Ho Kang¹

Department of Urology, Korea University College of Medicine, Seoul, Kyungpook National University School of Medicine, Daegu, KyungHee University College of Medicine, Seoul, Busan National University Yangsan Hospital, Yangsan, Inje University Busan Paik Hospital, Busan, Sungkyunkwan University School of Medicine, Seoul, Seoul National University College of Medicine, Seoul, College of Medicine, The Catholic University of Korea, Seoul, Yonsei University College of Medicine, Seoul, Hallym University School of Medicine, Seoul, Hanyang University College of Medicine, Seoul, Korea

Purpose: Robot-assisted radical cystectomy (RARC) optimizes patient recovery and has outcomes comparable with those of open surgery. This study aimed to compare the perioperative and oncologic outcomes of RARC in female and male patients.

Materials and Methods: A retrospective cohort study of the Korean Robot-Assisted Radical Cystectomy Study Group database from 2007 to 2019 identified 749 patients (111 females and 638 males). Female were matched 1:1 to male by propensity score matching using a logistic regression. We compared perioperative outcomes, oncologic outcomes, and complications between the two groups.

Results: The female group had comparable perioperative outcomes to the male group in terms of operation time, lymph node yield, positive surgical margin, blood transfusion rate, and hospitalization days. Complication rate and grade were not significantly different between the two groups. The most common complication was infection in female and gastrointestinal complications in male. We compared the 5-year overall, disease-specific, and recurrence-free survival of female and male: 58.2% vs. 68.0% (p=0.495), 75.7% vs. 79.3% (p=0.645), and 40.8% vs. 53.5% (p=0.913), respectively. On multivariable analysis, T stage (>T2), postoperative complications, and positive surgical margin were prognostic factors of poor outcome. Sex was not an independent predictor of the three survivals.

Conclusions: The current study suggests that RARC in female has comparable perioperative and oncologic outcomes to those in male. The complication rate of RARC in female was comparable to that in male, but the type of complications differed by sex.

Keywords: Cystectomy; Female; Robotic surgical procedures; Treatment outcome; Urinary bladder neoplasms

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
INTRODUCTION

Minimally invasive surgery is used in the treatment of bladder cancer to optimize patient recovery by reducing blood loss and postoperative complications. Since the advent of robot-assisted radical cystectomy (RARC), many studies have reported that the oncologic outcomes and complications of RARC are comparable to those of open radical cystectomy (ORC) [1]. In the Robot-Assisted Radical Cystectomy Versus Open Radical Cystectomy (RAZOR) trial, robotic cystectomy was noninferior to open cystectomy in terms of early oncologic outcomes [2]. The International Robotic Cystectomy Consortium (IRCC) database also reported comparable long-term oncologic outcomes for RARC and ORC [3,4]. In a single-institutional study, RARC with intracorporeal urinary diversion had comparable midterm oncologic outcomes to ORC [5]. Functional outcomes of RARC have been reported in a randomized controlled setting and proven to be comparable to ORC. Mastroianni et al. [6] suggested that RARC with intracorporeal urinary diversion has equivalence to ORC for most health-related quality of life measures.

Although the oncologic and functional outcomes of RARC have been validated, there is sparse literature evaluating the perioperative and oncologic outcomes of RARC in women. Bladder cancer has been reported to have more unsatisfactory outcomes in women than in men. In patients who undergo radical cystectomy, female gender is associated with worse overall, cancer-specific, and recurrence-free survival (RFS) [7-9] because of multifactorial etiologies, such as carcinogen exposure and anatomic, genetic, hormonal, and socioeconomic differences [10,11]. In the diversion of RARC, orthotopic bladder substitution is not frequently performed in female patients because orthotopic bladder substitution in women is associated with urinary retention [12,13] and urethral recurrence [14]. Moreover, little is known about the nerves-sparing technique in female patients. This study aimed to compare the perioperative and oncologic outcomes of RARC in female and male.

MATERIALS AND METHODS

Data from 749 patients in the Korean Robot-Assisted Radical Cystectomy Study Group (KORARC) database who underwent robotic radical cystectomy between April 2007 and November 2019 in 11 tertiary referral centers (21 surgeons) in the Republic of Korea were collected and analyzed retrospectively. The KORARC database is a web-based electronic database originating from the Korean Society of Endourology and Robotics. All analyses were performed in accordance with the Declaration of Helsinki after approval by the Institutional Review Board of the Korea University Anam Hospital (approval number: 2019AN0102). Written informed consent was obtained from all study participants.

All 749 patients with a mean follow-up of 30.8 months were categorized into two groups (111 females and 638 males). The female patients were propensity-score-matched with the male patients because of the wide differences in sample size between the two groups. Demographics, preoperative treatment, clinical stage before RARC, preoperative laboratory findings, intraoperative outcomes, oncologic outcomes, and complications were compared between the two groups. Both clinical and pathologic stages were classified according to the American Joint Committee on Cancer TNM staging system.

1. Surgical technique

RARC was performed using a six-port transperitoneal approach with the DaVinci Surgical System (Intuitive Surgical Inc., Sunnyvale, CA, USA). Cystoprostatectomy was performed in male patients, whereas female patients had either anterior pelvic exenteration or reproductive-organ-sparing cystectomy (preservation of the uterus, vagina, and bilateral ovaries) [15]. Pelvic lymph node (LN) dissection was performed in standard, extended, or limited regions [16].

A urinary diversion was made as an orthotopic bladder substitution, ileal conduit pouch, or ureterocutaneousostomy using either an extracorporeal or intracorporeal approach. Decision on the type of urinary diversion was made with consideration of age, sex, patient counsel, tumor location, and each surgeon’s experience and preference. Orthotopic bladder substitution was performed in patients without any urethral stricture or urethral tumor invasion, insufficient length of small bowel to be harvested for neobladder, short ureteral length due to a repeatedly positive ureteral frozen margin, or other technical issues making orthotopic bladder substitution impossible. Nerve sparing was performed on the unilateral or bilateral side, if indicated, in both groups.

2. Perioperative outcomes and follow-up

Perioperative outcomes included total operation time, open conversion rate, extent of LN dissection, number of LN yields, estimated blood loss, blood transfusion rate, transfusion amount, and hospitalization days. Pathologic T and N stage, number of positive LNs, positive surgical margin (PSM), and histology were compared between the two groups. Complications were based on the Clavien–Dindo classification system.

Patients were followed up after RARC with radiologic evaluation to identify any local or metastatic recurrence.
Oncologic outcomes included overall survival (OS), diseasespecific survival (DSS), and RFS. OS was defined as the time from RARC to death, including death due to any cause; DSS was defined as the time from RARC to death due to bladder cancer; and RFS was defined as the time from RARC to local or metastatic recurrence.

3. Statistical analysis

We used an independent two-sample t-test to analyze the quantitative variables. Values of quantitative variables are presented as means with standard deviation or medians with interquartile range. Qualitative variables were compared using the chi-square test and Fisher’s exact test. To reduce the imbalance in sample size and covariates, we performed propensity-score-matched analysis.

Kaplan–Meier curves were used to depict OS, DSS, and RFS. Multivariable analysis using the Cox proportional hazards model with backward selection was used to identify independent predictors of all three survivals. Multivariable analysis included variables such as institution; sex; age; body mass index; American Society of Anesthesiology (ASA) score; history of abdominal surgery; underlying cardiac, pulmonary, or renal disease; hypertension; diabetes mellitus; neoadjuvant chemotherapy; preoperative hemoglobin level; glomerular filtration rate; albumin level; number of LN yields; type of urinary diversion; corporeal type; pathologic T stage greater than T2; pathologic N stage; PSM; and postoperative complications. All statistical analyses were performed using IBM SPSS Statistics 25 (IBM Corp., Armonk, NY, USA). Statistical significance was defined as p<0.05.

4. Propensity score matching

Females were matched 1:1 to males by propensity score matching using a logistic regression. In propensity score matching, we used 18 clinical covariates: age; body mass index; ASA score; history of abdominal surgery; underlying cardiac, pulmonary, or renal disease; hypertension; diabetes mellitus; smoking history; neoadjuvant chemotherapy; clinical T and N stage; preoperative hemoglobin level; glomerular filtration rate; albumin level; type of urinary diversion; corporeal type; and nerve sparing. After the matching, the baseline characteristics of the two groups were compared to evaluate the quality of covariate balance.

RESULTS

1. Baseline characteristics

The baseline characteristics of the two groups before and after the propensity-matched analysis are depicted in Table 1. Before matching, the male group had a higher smoking rate than their female counterparts, whereas more female patients than male patients had a history of abdominal surgeries. Of the 749 patients, female had less orthotopic bladder substitution and nerve-sparing procedures than did male. After the propensity-matched analysis, 67 patients were assigned to each group. The baseline characteristics of the two groups were not significantly different (Table 1).

2. Perioperative outcomes

Female had similar perioperative outcomes to male as listed in Table 2. The median LN yield was 17 in both groups (p=0.351). None of the 134 patients had conversion to open surgery during RARC. The complication rate was 63.6% in female and 58.2% in male (p=0.521), demonstrating that radical cystectomy still results in high morbidity. Both groups had grade II complications most often, according to the Clavien–Dindo classification. None of the patients had grade V complications. In female patients, the most frequent type of complication was postoperative infection, including urinary tract infection, acute pyelonephritis, wound infection, and bacteremia (28.8%), while in male patients, gastrointestinal complications, including paralytic/mechanical ileus, inguinal hernia, and incisional hernia, were the most common type (25.4%) (Table 2).

3. Oncologic outcomes

Pathologic T stage, N stage, and positive LNs were not significantly different between the two groups. PSM was 3.0% in female and 4.5% in male (p>0.999). At 5 years postoperatively, OS was 58.2% and 68.0%, DSS was 75.7% and 79.3%, and RFS was 40.8% and 53.5% in female and male, respectively (Table 3).

In the multivariable analysis, patients with ASA 3 status had significantly worse OS than did those with ASA 1 status. Pathologic T stage greater than T2 was associated with worse OS, DSS, and RFS. Postoperative complications were associated with worse OS and DSS. PSM was associated with worse RFS (Table 4).

The Kaplan–Meier survival analysis of OS, DSS, and RFS by sex, T stage, and complication status is depicted in Figs. 1-3. OS differed by ASA classification and RFS differed by margin status in the Kaplan–Meier analysis (Fig. 4).

DISCUSSION

We compared 111 females and 638 males who underwent RARC, which is a relatively large sample size. Before the matched analysis, the percentage of orthotopic bladder sub-
| Parameter | Before propensity matching | After propensity matching |
|-----------|---------------------------|----------------------------|
|           | Female (n=111) | Male (n=638) | p-value | Female (n=67) | Male (n=67) | p-value |
| Age (y)   | 68.0 (58.0–74.0) | 68.0 (58.0–74.0) | 0.437 | 68.0 (60.0–74.0) | 68.0 (61.0–75.0) | 0.515 |
| BMI (kg/m²) | 23.5 (21.4–26.7) | 24.2 (22.3–26.2) | 0.679 | 23.6 (21.8–27.7) | 24.1 (22.3–26.2) | 0.994 |
| ASA score | | | 0.430 | | | 0.979 |
| ASA 1     | 27 (24.3) | 189 (29.8) | 16 (23.9) | 17 (25.4) |
| ASA 2     | 73 (65.8) | 397 (62.5) | 42 (62.7) | 41 (61.2) |
| ASA 3     | 11 (9.9) | 49 (7.7) | 9 (13.4) | 9 (13.4) |
| Underlying disease | | | | | | |
| Cardiac   | 7 (6.3) | 68 (10.7) | 5 (7.5) | 5 (7.5) | >0.999 |
| Pulmonary | 6 (5.4) | 46 (7.2) | 5 (7.5) | 4 (6.0) | >0.999 |
| Renal     | 17 (15.3) | 103 (16.1) | 12 (17.9) | 13 (19.4) | 0.825 |
| HTN       | 47 (42.3) | 277 (43.4) | 26 (38.8) | 27 (40.3) | 0.860 |
| DM        | 25 (22.5) | 148 (23.2) | 15 (22.4) | 15 (22.4) | >0.999 |
| Smoking   | | | 0.604 |
| None      | 108 (97.3) | 281 (44.4) | 64 (95.5) | 65 (97.0) |
| Former smoker | 2 (1.8) | 266 (42.0) | 2 (3.0) | 2 (3.0) |
| Current smoker | 1 (0.9) | 86 (13.6) | 1 (1.5) | 0 (0.0) |
| Prior abdominal surgery | 43 (40.6) | 137 (21.9) | 26 (38.8) | 20 (29.9) | 0.275 |
| Family history of cancer | 4 (3.6) | 19 (3.0) | 3 (4.5) | 1 (1.5) | 0.365 |
| Prior treatment | | | | | | |
| Number of TURBT | 1.33±1.09 | 1.52±1.27 | 1.39±1.26 | 1.43±1.13 | 0.829 |
| Intravesical therapy | 16 (14.4) | 85 (13.3) | 9 (13.4) | 10 (14.9) | 0.804 |
| Neoadjuvant chemotherapy | 14 (12.7) | 110 (17.4) | 9 (13.4) | 9 (13.4) | >0.999 |
| Prior partial cystectomy | 3 (3.5) | 11 (2.2) | 2 (3.6) | 0 (0.0) | 0.496 |
| Clinical T stage | | | | | | |
| NMIBC | 36 (34.0) | 223 (37.4) | 23 (34.3) | 20 (29.9) | 0.896 |
| T2 | 54 (50.9) | 282 (47.2) | 33 (49.3) | 35 (52.2) | 0.292 |
| T3 | 15 (14.2) | 73 (12.2) | 10 (14.9) | 10 (14.9) | 0.927 |
| T4 | 1 (0.9) | 19 (3.2) | 1 (1.5) | 2 (3.0) | 0.961 |
| Clinical N stage | | | | | | |
| N0 | 99 (93.4) | 552 (95.2) | 63 (94.0) | 62 (92.5) | 0.670 |
| N1 | 4 (3.8) | 15 (2.6) | 3 (4.5) | 4 (6.0) | 0.833 |
| N2 | 1 (0.9) | 10 (1.7) | 1 (1.5) | 1 (1.5) | 0.916 |
| N3 | 2 (1.9) | 3 (0.5) | 0 (0.0) | 0 (0.0) | 0.985 |
| Laboratory findings | | | | | | |
| Hb (g/dL) | 11.6 (10.3–12.6) | 13.2 (11.6–14.4) | <0.001 | 11.7 (10.8–12.6) | 12.1 (10.0–13.2) | 0.961 |
| GFR (mL/min/1.73 m²) | 78.0 (58.2–93.3) | 77.0 (62.0–91.3) | 0.710 | 79.0 (58.6–93.1) | 77.0 (59.5–90.4) | 0.670 |
| Albumin (g/dL) | 4.0 (3.5–4.3) | 4.1 (3.6–4.4) | 0.013 | 4.0 (3.5–4.3) | 3.8 (3.3–4.3) | 0.833 |
| PLT (×10³/μL) | 242 (196–290) | 218 (175–265) | 0.005 | 231 (194–290) | 217 (187–265) | 0.491 |
| Diversion type | | | 0.028 |
| Orthotopic bladder | 47 (44.8) | 356 (58.7) | 29 (43.3) | 30 (44.8) |
| Ileal conduit pouch | 53 (50.5) | 228 (37.6) | 37 (55.2) | 36 (53.7) |
| Ureterocutaneostomy | 5 (4.8) | 22 (3.6) | 1 (1.5) | 1 (1.5) | 0.985 |
| Corporeal type | | | 0.921 | | | 0.999 |
| Intracorporeal | 28 (26.4) | 163 (26.0) | 17 (25.4) | 17 (25.4) | 0.999 |
| Extracorporeal | 78 (73.6) | 465 (74.0) | 50 (74.6) | 50 (74.6) | 0.999 |
| Nerve sparing | 16 (14.4) | 288 (45.8) | <0.001 | 14 (20.9) | 14 (20.9) | 0.999 |

Values are presented as median (interquartile range), number (%), or mean±standard deviation. BMI, body mass index; ASA, American Society of Anesthesiology; HTN, hypertension; DM, diabetes mellitus; TURBT, transurethral resection of bladder tumor; NMIBC, non-muscle-invasive bladder cancer; Hb, hemoglobin; GFR, glomerular filtration rate; PLT, platelet.
urology.org

Gender-related outcomes in RARC

The overall rates of orthotopic bladder substitution in our study were higher than those reported in prior studies. For example, Groeben et al. [19] compared rates of continent urinary diversion in the United States and Germany. They reported that continent urinary diversion was performed in 8.6% of male patients and 4.1% of female patients in the United States. In Germany, 37.4% of male patients and 209% of female patients had continent diversion. Age, female gender, and low-volume center were predictors of incontinent urinary diversion in a multivariable analysis. In our study, the relatively high rate of continent urinary diversion could be explained by our use of a database based on a high-volume center and surgeons with proficient surgical technique.

Table 2. Perioperative outcomes and complications

| Parameter                  | Female | Male   | p-value |
|---------------------------|--------|--------|---------|
| OP time (min)             | 425 (338–553) | 430 (340–550) | 0.491   |
| Open conversion rate      | 0 (0.0) | 0 (0.0) | >0.999  |
| LN dissection             | 0.184  |        |         |
| Standard                  | 12 (23.5) | 10 (20.0) |         |
| Extended                  | 36 (70.6) | 40 (80.0) |         |
| Limited                   | 3 (5.9)  | 0 (0.0)  |         |
| LN yield (n)              | 17 (10–26) | 17 (11–24) | 0.351   |
| EBL (mL)                  | 400 (200–600) | 400 (300–600) | 0.346   |
| Blood transfusion rate    | 13 (19.7) | 15 (22.7) | 0.670   |
| Transfusion (mL)          | 320 (267.5–605) | 320 (320–640) | 0.634   |
| Hospitalization (d)      | 14 (12–18.5) | 15 (12–21.25) | 0.077   |
| Readmission rate          | 35 (53.0) | 31 (46.3) | 0.436   |
| Complication rate         | 42 (63.6) | 39 (58.2) | 0.521   |
| Clavien–Dindo grade       |         |        | 0.588   |
| Grade I                   | 4 (9.5)  | 1 (2.6)  |         |
| Grade II                  | 21 (50.0) | 21 (53.8) |         |
| Grade III                 | 15 (35.7) | 14 (35.9) |         |
| Grade IV                  | 2 (4.8)  | 3 (7.7)  |         |
| Type of complications     |         |        |         |
| Gastrointestinal          | 6 (9.1)  | 17 (25.4) | 0.013   |
| Cardiovascular            | 1 (1.5)  | 0 (0.0)  | 0.496   |
| Pulmonary                 | 1 (1.5)  | 0 (0.0)  | 0.496   |
| Genitourinary             | 12 (18.2) | 9 (13.4)  | 0.453   |
| Infection                 | 19 (28.8) | 12 (17.9) | 0.138   |
| Wound                     | 5 (7.6)  | 6 (9.0)  | 0.773   |
| Vascular                  | 4 (6.1)  | 1 (1.5)  | 0.208   |
| Hematological             | 1 (1.5)  | 3 (4.5)  | 0.619   |
| Neurological              | 1 (1.5)  | 0 (0.0)  | 0.496   |
| Etc.                      | 10 (15.2) | 6 (9.0)   | 0.272   |

Values are presented as median (interquartile range) or number (%). OP, operation; LN, lymph node; EBL, estimated blood loss.

Table 3. Oncologic outcomes

| Parameter | Female | Male   | p-value |
|-----------|--------|--------|---------|
| T stage   |        |        | 0.407   |
| T0        | 3 (4.5) | 4 (6.2) |         |
| Tis       | 6 (9.0) | 0 (0.0) |         |
| Ta        | 4 (6.0) | 2 (3.1) |         |
| T1        | 8 (11.9)| 8 (12.5)|         |
| T2        |        |        |         |
| T2a       | 9 (13.4)| 12 (18.8)|       |
| T2b       | 8 (11.9)| 10 (15.6)|       |
| T3        |        |        |         |
| T3a       | 16 (23.9)| 12 (18.8)|       |
| T3b       | 8 (11.9)| 10 (15.6)|       |
| T4        |        |        |         |
| T4a       | 5 (7.5) | 6 (9.4) |         |
| T4b       | 0 (0.0) | 0 (0.0) |         |
| N stage   |        |        | 0.999   |
| N0        | 49 (75.4)| 48 (76.2)|       |
| N1        | 10 (15.4)| 9 (14.3) |         |
| N2        | 5 (7.7) | 5 (7.9) |         |
| N3        | 1 (1.5) | 1 (1.6) |         |
| Positive LN (n) | 0.74±2.08 | 0.80±2.44 | 0.884 |
| PSM       | 2 (3.0) | 3 (4.5) | >0.999  |
| Histology |        |        |         |
| ALI       | 24 (35.8)| 24 (36.9)| 0.895   |
| PNI       | 11 (16.7)| 18 (28.1)| 0.117   |
| Squamous metaplasia | 8 (12.1) | 4 (6.2) | 0.248   |
| Glandular metaplasia | 3 (4.5) | 4 (6.2) | 0.716   |
| 2-y survival |        |        |         |
| OS        | 88.7    | 74.1   |         |
| DSS       | 92.6    | 82.6   |         |
| RFS       | 62.5    | 60.1   |         |
| 5-y survival |        |        |         |
| OS        | 58.2    | 68.0   |         |
| DSS       | 75.7    | 79.3   |         |
| RFS       | 40.8    | 53.5   |         |

Values are presented as number (%), mean±standard deviation, or percentage only.
LN, lymph node; PSM, positive surgical margin; ALI, angiolymphatic invasion; PNI, perineural invasion; OS, overall survival; DSS, disease-specific survival; RFS, recurrence-free survival.
### Table 4. Multivariable analysis of OS, DSS, and RFS by Cox proportional hazards model with backward selection

| Survival Parameter | HR          | 95% CI            | p-value |
|--------------------|-------------|-------------------|---------|
| OS (n=116) ASA     |             |                   |         |
| ASA 1              | 1           |                   |         |
| ASA 2              | 3.613       | (0.986–13.238)    | 0.052   |
| ASA 3              | 6.643       | (1.350–32.696)    | 0.020   |
| T stage (>T2 vs. T0–T2) | 2.521       | (1.038–6.124)     | 0.041   |
| Complication       | 3.488       | (1.268–9.599)     | 0.016   |
| DSS (n=113) T stage (>T2 vs. T0–T2) | 4.365       | (1.298–14.678)    | 0.017   |
| Complication       | 9.097       | (1.72–70.634)     | 0.035   |
| RSS (n=118) T stage (>T2 vs. T0–T2) | 2.713       | (1.459–5.046)     | 0.002   |
| Positive surgical margin | 3.351       | (1.136–9.886)     | 0.028   |
| Complication       | 1.942       | (0.988–3.817)     | 0.054   |

OS, overall survival; DSS, disease-specific survival; RFS, recurrence-free survival; HR, hazard ratio; CI, confidence interval; ASA, American Society of Anesthesiology.

![Graph A](image1.png)

**Fig. 1.** Kaplan–Meier survival analysis of (A) overall survival, (B) disease-specific survival, and (C) recurrence-free survival by sex.

![Graph A](image2.png)

**Fig. 2.** Kaplan–Meier survival analysis of (A) overall survival, (B) disease-specific survival, and (C) recurrence-free survival by T stage. NMIBC, non-muscle-invasive bladder cancer.
in orthotopic bladder substitution.

The percentage of nerve-sparing procedures was 14.4% of female RARC cases and 45.8% of male RARC cases before the propensity-score-matched analysis. Nerve sparing in female radical cystectomy is a challenging and poorly understood procedure. Bhatta Dhar et al. [20] and Hinata et al. [21] demonstrated the anatomy and surgical procedure of nerve-sparing dissection in female radical cystectomy. However, reports on the oncologic and functional outcomes of the nerve-sparing technique in female radical cystectomy are lacking. The infrequent performance of nerve sparing in female RARC is due to this lack of evidence and it being an unfamiliar technique.

By using propensity-score-matched analysis, we could control for potential confounding variables such as diversion type, corporeal type, and nerve sparing. We found that RARC presented comparable perioperative outcomes and complications in female patients as in their male counterparts. However, the patterns of complications differed. In the female group, the most common complication was infection (28.8%). On the other hand, the male group experienced gastrointestinal complications the most often (25.4%). Abdi et al. [22] found that female gender is associated with a higher postoperative infection rate in radical cystectomy. Vaginal microflora may play a role in surgical site infection, but the mechanism is not clear. Future studies are required to investigate the effect of vaginal flora on infection after radical cystectomy in women. Information about the bacteria cultured at the site of infection would be helpful.

The oncologic outcomes of historical ORC or RARC reports are listed in Table 5 [3,4,23-26]. In the present study, a PSM was found in 30% of female undergoing RARC and in

![Fig. 3. Kaplan–Meier survival analysis of (A) overall survival, (B) disease-specific survival, and (C) recurrence-free survival by complication status.](image)

![Fig. 4. Kaplan–Meier survival analysis of (A) overall survival by ASA classification and (B) recurrence-free survival by margin status. ASA, American Society of Anesthesiology.](image)
4.5% of male, which is comparable with the rates reported in previous studies [2-4,26]. In our study, 5-year OS, DSS, and RFS were lower in female RARC patients than in their male counterparts. Previous studies have reported that female gender is a poor prognostic factor in bladder cancer [7-9]. For example, Kluth et al. [7] investigated 8,102 patients (1,605 women) who underwent radical cystectomy for urothelial carcinoma of the bladder and reported that female gender was associated with cancer-specific mortality. To explain the gender disparity, multifactorial etiologies such as carcinogen exposure and anatomic, genetic, hormonal, and socioeconomic differences have been suggested [10,11]. Although the more advanced disease presentation in women than in men could contribute to the difference in survival, women still had worse prognosis in stage-adjusted analysis [27]. Hormonal etiologies have been suggested, such as androgen receptor and estrogen receptor, yet the mechanisms are under investigation [28,29]. Inequalities in health care may be one of the etiologies that explain the compromising outcomes. To compensate for this bias, we included the institution as one of the variables in the Cox proportional hazards model. Since the present study had a retrospective design, the database is dependent on review of medical records. This could result in some missing information. Selection and recall biases could also occur. Second, long-term follow-up data and functional outcomes are needed to further compare the outcomes between the two groups. Third, neoadjuvant chemotherapy was administered to 12.7% of the female group and 17.4% of the male group, which was relatively low. Variables such as cycles and types of neoadjuvant chemotherapy were missed. Fourth, this study did not have a central pathologist and as such interobserver variability in pathologic reports could occur.

CONCLUSIONS

The perioperative outcomes in female RARC patients were comparable to those of the male counterparts. Female gender was not associated with poor oncologic outcomes in this study. Complication rate and grade of the female patients were similar to those of the male patients. However, complication type differed by sex.

CONFLICTS OF INTEREST

The authors have nothing to disclose.
Gender-related outcomes in RARC

ACKNOWLEDGMENTS

This research was supported by a Korean Society of Endourology and Robotics (KSER) Grant.

AUTHORS’ CONTRIBUTIONS

Research conception and design: Hyun Jung Jin, Ji Sung Shim, Ja Hyeon Ku, and Seok Ho Kang. Data acquisition: Hyun Jung Jin, Tae Gyun Kwon, Tae-Hwan Kim, Seung Hyun Jeon, Sang Hyub Lee, Sung Gu Kang, Jong Kil Nam, Wan Suk Kim, Byung Chang Jeong, Jong Jin Oh, Sang Chul Lee, Ji Youl Lee, Sung-Hoo Hong, Koon Ho Rha, Woong Kyu Han, Won Sik Ham, Young Goo Lee, Yong Seong Lee, Sung Yul Park, Young Eun Yoon, Ja Hyeon Ku, and Seok Ho Kang. Statistical analysis: Hyun Jung Jin and Ji Sung Shim. Data analysis and interpretation: Hyun Jung Jin and Ji Sung Shim. Drafting of the manuscript: Hyun Jung Jin. Critical revision of the manuscript: Ji Sung Shim, Ja Hyeon Ku, and Seok Ho Kang. Obtaining funding: Ja Hyeon Ku and Seok Ho Kang. Administrative, technical, or material support: Ji Sung Shim. Supervision: Ja Hyeon Ku and Seok Ho Kang. Approval of the final manuscript: Ja Hyeon Ku and Seok Ho Kang.

REFERENCES

1. Tyritzis SI, Collins JW, Wiklund NP. The current status of robot-assisted cystectomy. Indian J Urol 2018;34:101-9.
2. Parekh DJ, Reis IM, Castle EP, Gonzalgo ML, Woods ME, Svatek RS, et al. Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial. Lancet 2018;391:2525-36.
3. Hussein AA, Elsayed AS, Aldhaam NA, Jing Z, Osei J, Kaouk J, et al. Ten-year oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. J Urol 2019;202:927-35.
4. Raza SJ, Wilson T, Peabody JO, Wiklund P, Scherr DS, Al-Daghmin A, et al. Long-term oncologic outcomes following robot-assisted radical cystectomy: results from the International Robotic Cystectomy Consortium. Eur Urol 2015;68:721-8.
5. Simone G, Tuderti G, Misuraca L, Anceschi U, Ferriero M, Minisola F, et al. Perioperative and mid-term oncologic outcomes of robotic assisted radical cystectomy with totally intracorporeal neobladder: results of a propensity score matched comparison with open cohort from a single-centre series. Eur J Surg Oncol 2018;44:1432-8.
6. Mastroianni R, Tuderti G, Anceschi U, Bove AM, Brassetti A, Ferriero M, et al. Comparison of patient-reported health-related quality of life between open radical cystectomy and robot-assisted radical cystectomy with intracorporeal urinary diversion: interim analysis of a randomised controlled trial. Eur Urol Focus 2021 Mar 9 [Epub]. https://doi.org/10.1016/j.euf.2021.03.002.
7. Kluth LA, Rieken M, Xylinas E, Kent M, Rink M, Rouprêt M, et al. Gender-specific differences in clinicopathologic outcomes following radical cystectomy: an international multi-institutional study of more than 8000 patients. Eur Urol 2014;66:913-9.
8. Uhlig A, Seif Amir Hosseini A, Simon J, Lotz J, Trojan L, Schmid M, et al. Gender specific differences in disease-free, cancer specific and overall survival after radical cystectomy for bladder cancer: a systematic review and meta-analysis. J Urol 2018;200:48-60.
9. Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, et al. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 2014;83:863-7.
10. Dobruch J, Daneshmand S, Fisch M, Lotan Y, Noon AP, Resnick MJ, et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. Eur Urol 2016;69:300-10.
11. Shariat SF, Sfakianos JP, Droller MJ, Karakiewicz PI, Meryn S, Bochner BH. The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010;105:300-8.
12. Ali-El-Dein B, Gomha M, Ghoneim MA. Critical evaluation of the problem of chronic urinary retention after orthotopic bladder substitution in women. J Urol 2002;168:587-92.
13. Finley DS, Lee U, McDonough D, Raz S, deKernion J. Urinary retention after orthotopic neobladder substitution in females. J Urol 2011;186:1364-9.
14. Ali-El-Dein B, Abdel-Latif M, Ashamallah A, Abdel-Rahim M, Ghoneim M. Local urethral recurrence after radical cystectomy and orthotopic bladder substitution in women: a prospective study. J Urol 2004;171:275-8.
15. Tae JH, Pyun JH, Shim JS, Cho S, Kang SG, Ko YH, et al. Oncological and functional outcomes of robot-assisted radical cystectomy in bladder cancer patients in a single tertiary center: can these be preserved throughout the learning curve? Investig Clin Urol 2019;60:463-71.
16. Sundi D, Svatek RS, Nielsen ME, Schoenberg MP, Bivalacqua TJ. Extent of pelvic lymph node dissection during radical cystectomy: is bigger better? Rev Urol 2014;16:159-66.
17. Gross T, Furrer M, Schorno P, Wuehrich PY, Schneider MP, Thalmann GN, et al. Reproductive organ-sparing cystectomy significantly improves continence in women after orthotopic bladder substitution without affecting oncological outcome.
18. Veskimäe E, Neuzillet Y, Rouanney M, MacLennan S, Lam TBL, Yuan Y, et al. Systematic review of the oncological and functional outcomes of pelvic organ-preserving radical cystectomy (RC) compared with standard RC in women who undergo curative surgery and orthotopic neobladder substitution for bladder cancer. BJU Int 2017;120:12-24.
19. Groeben C, Koch R, Baunacke M, Schmid M, Borkowetz A, Wirth MP, et al. Urinary diversion after radical cystectomy for bladder cancer: comparing trends in the US and Germany from 2006 to 2014. Ann Surg Oncol 2018;25:3502-9.
20. Bhatia Dhar N, Kessler TM, Mills RD, Burkhard F, Studer UE. Nerve-sparing radical cystectomy and orthotopic bladder replacement in female patients. Eur Urol 2007;52:1006-14.
21. Hinata N, Hussein AA, Bando Y, Terakawa T, Murakami G, Yamamoto M, et al. Histologic investigation of the female vesicourethral junction and adjacent tissues for nerve-sparing radical cystectomy. Urology 2021;149:161-7.
22. Abdi H, Elzayat E, Cagiannos I, Lavallée LT, Cnossen S, Flaman AS, et al. Female radical cystectomy patients have a higher risk of surgical site infections. Urol Oncol 2018;36:400.e1-5.
23. Ghoneim MA, Abdel-Latif M, el-Mekresh M, Abol-Enein H, Mosbah A, Ashamallah A, et al. Radical cystectomy for carcinoma of the bladder: 2,720 consecutive cases 5 years later. J Urol 2008;180:121-7.
24. Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666-75.
25. Hautmann RE, de Petroni RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61:1039-47.
26. Zhang JH, Ericson KJ, Thomas LJ, Knorr J, Khanna A, Crane A, et al. Large single institution comparison of perioperative outcomes and complications of open radical cystectomy, intracorporeal robot-assisted radical cystectomy and robotic extracorporeal approach. J Urol 2020;203:512-21.
27. Mungan NA, Aben KK, Schoenberg MP, Visser O, Coebergh JW, Witjes JA, et al. Gender differences in stage-adjusted bladder cancer survival. Urology 2000;55:876-80.
28. Boorjian S, Ugras S, Mongan NP, Gudas LJ, You X, Tickoo SK, et al. Androgen receptor expression is inversely correlated with pathologic tumor stage in bladder cancer. Urology 2004;64:383-8.
29. Shen SS, Smith CL, Hsieh JT, Yu J, Kim IY, Jian W, et al. Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue. Cancer 2006;106:2610-6.
30. Smith ND, Prasad SM, Patel AR, Weiner AB, Pariser JJ, Razmaria A, et al. Bladder cancer mortality in the United States: a geographic and temporal analysis of socioeconomic and environmental factors. J Urol 2016;195:290-6.